Pharmacokinetics, Target Engagement of an Immunoproteasome Subunit Low-Molecular-Mass Polypeptide‑2 (LMP2) Inhibitor AR-01, and Its Anti-Alzheimer's Effects in Rodents. [PDF]
ACS Pharmacol Transl SciThapa Magar TB +7 more
europepmc +1 more source
Targeting Epstein-Barr Virus for Cancer Vaccines: Recent Advances and Future Directions. [PDF]
Cancer Commun (Lond)Lin G, Chen Z, Zhong Q, Sun C, Zeng MS.
europepmc +1 more source
Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review. [PDF]
Lancet Reg Health West PacFeng SY, Shu RJ, Liu N, Ma J.
europepmc +1 more source
A Linear-Scaling Integral-Direct Explicitly Correlated Second-Order Møller-Plesset Approach. [PDF]
J Chem Theory ComputKállay M +3 more
europepmc +1 more source
Recent advances in Epstein-Barr virus vaccines development from mechanistic exploration to clinical translation. [PDF]
NPJ VaccinesHong L +7 more
europepmc +1 more source
The immunoproteasome as a neuroimmune hub in the central nervous system: from proteostasis stress to inflammatory pathology. [PDF]
J NeuroinflammationZhao H, Liu Y, Chen X.
europepmc +1 more source
CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects. [PDF]
Rev Med VirolAllehyani N +7 more
europepmc +1 more source
Epstein-Barr Virus-Mediated Apoptosis Evasion in Epithelial Malignancies: Molecular Mechanisms and Therapeutic Implications. [PDF]
Biology (Basel)Blanco R, Soto C, Muñoz JP.
europepmc +1 more source